Rainier Rehab Logo
Editorial illustration of a row of tall narrow institutional door panels receding across a pale…
November 15, 20269 min read

New Mexico Treated 1,407 Inmates for Addiction This Year. Twelve Months Ago the Number Was 176.

The number that matters in New Mexico's prison addiction program is not the budget. It is the ratio between two figures that appeared eleven slides apart in a presentation delivered to state lawmakers on November 12.

The first is 2,000 — the Corrections Department's own estimate of how many people in its custody meet the medical criteria for a substance use disorder, drawn from a survey that put the share at 36 percent of the state prison population. The second is 1,407, the count of inmates who received medication-assisted treatment during the program's current year. Of those, 815 were still active when the fiscal analyst compiled the numbers. Seven of New Mexico's eight state-operated prisons now dispense treatment medications.

A year earlier, the Legislative Finance Committee reported that 176 inmates had received the treatment.

That is an eightfold increase in twelve months, and it is the kind of jump that usually signals either a genuine operational turn or a reporting change. In this case the slide deck, prepared by LFC senior fiscal analyst Allegra Hernandez, supports the first reading: the phases, the spending, and the constraints all line up with a program that was slow to start and is now moving, just not fast enough to reach the population it was funded for.

What the state actually bought

The Legislature has appropriated $136.2 million for medication-assisted treatment for justice-involved New Mexicans since fiscal year 2024. Very little of it moved for the first two years — that was the substance of a November 2025 LFC handout, which said plainly that funding "has been slow to roll out, and few adults have received services in comparison to how many adults need the services."

The prison-specific piece is smaller and more recent. The Corrections Department received a three-year appropriation of $33.9 million through the state's Government Results and Opportunity program, covering fiscal years 2026 through 2028. Through fiscal 2026 and the year-to-date of fiscal 2027, the program has spent $3.7 million of it.

Eleven percent of a three-year budget in roughly a year and a half is not a scandal in a program that had to hire clinicians and write clinical protocols first.

The number the state needs before it asks for more

It is, however, the figure that determines whether the department can absorb the program into its base budget when the pilot expires, and the analyst's presentation says the state will want "strong evidence of the efficacy of the program" before that happens.

There is an arithmetic floor underneath the ask. The estimated monthly medication cost runs $380 to $437 per inmate. Multiply the upper bound across twelve months and the 2,000 people the state believes need treatment, and the result is $10.5 million a year — precisely the figure the presentation lists as the fiscal 2029 requirement if lawmakers were to fund the program fully after the GRO money ends. The price of universal coverage in New Mexico's prisons is not a mystery. It is a per-head medication rate times a census.

Buprenorphine was the open door. Methadone is the locked one.

The program's structure follows the pharmacology, and the pharmacology follows federal rule.

Year one, fiscal 2026, was about continuity: keep treating people who arrived already on buprenorphine, and by December 31, 2025 offer FDA-approved medications to anyone entering custody who was already engaged in treatment, as a clinical evaluation determines. Year two expands to every eligible person in custody and adds methadone and long-acting injectables "where clinically appropriate and operationally feasible." Year three is universal availability plus audits and outcome evaluation.

That middle clause is doing a lot of work, and the administrator who runs the program said so directly.

Wence Asonganyi, the Corrections Department's health services administrator, told the committee that establishing an in-house opioid treatment program has been the single biggest obstacle — multiple attempts through professional referral and a formal Request for Information went nowhere. The department can supply every other treatment medication from its own pharmacy. For methadone it depends on an outside provider to sign off, which leaves the state, in his words, "vulnerable."

The reason is structural rather than bureaucratic, and it is worth stating precisely.

What 42 CFR Part 8 means inside a prison

Buprenorphine can be prescribed by any clinician with a standard DEA registration. Methadone for opioid use disorder can only be dispensed through a federally certified, accredited opioid treatment program, under regulations at 42 CFR Part 8 — the same rule that decides where a clinic can open in rural Maine decides whether a state prison system can run methadone in-house. When the outside provider cannot deliver, a correctional health system has no lawful substitute, and patients in custody go into withdrawal on a schedule the state does not control.

Staffing is the second constraint, and it looks like the one the rest of the country is living through. Asonganyi said recruiting behavioral health clinicians for counseling and psychotherapy alongside the medication has been difficult, and that the department has plugged the gaps with telemedicine. Medication-assisted treatment by definition pairs the drug with psychosocial support; a prison system that can staff the pharmacy but not the group room is delivering half of the intervention.

The population the survey counts and the population the medicine treats

The 36 percent figure deserves a note that the presentation makes only implicitly. The survey counts substance use disorder broadly — stimulants, cannabis, alcohol, opioids. Medication-assisted treatment, as the LFC's own background slides state, works for opioid and alcohol use disorders, which the Health Care Authority estimates account for more than half of the state's SUD population.

So 2,000 is not the number of people who need a prescription. It is the number who meet medical criteria for a disorder, some subset of whom have a condition that has an FDA-approved medication. The state's reporting does not publish that subset, which means the 1,407 figure cannot be read as 70 percent of the treatable population. It is 70 percent of a broader denominator, and the true coverage rate is higher — how much higher is a question the Corrections Department has not been asked to answer in public.

The other number in the deck is the one with no national analogue: the Health Care Authority estimates more than 9,000 New Mexicans need medication-assisted treatment and are not receiving it. The prison program, at full capacity, would cover about a fifth of that gap from inside the walls.

Where the retention question hides

Between 1,407 people who received treatment and 815 who were still active sits a difference of 592. That gap is not necessarily failure — people are released, transferred, or finish a course of treatment — but the presentation does not decompose it, and the decomposition is the whole question for a correctional program.

A prison MAT system can be judged on initiation, which is easy to count and easy to celebrate, or on retention through the last weeks of custody, which is what determines whether someone walks out with a tolerance and no prescription. The state's own phase-three goals concede the point: continuity of care after release and outcome data collection are both listed as future work, not current practice.

There is a federal vehicle for part of that. In fiscal 2025 Washington approved New Mexico's application for an incarceration reentry initiative allowing Medicaid coverage for people in tribal, state and local correctional facilities, effective through 2029. The state's reentry program, JUST Health Plus, launched July 1, 2025 at three Corrections Department facilities, with the remaining state prisons, county jails and juvenile facilities to be phased in over the coming years at 12 to 15 months per phase.

Read the two timelines together and the shape of the next three years is visible: the treatment program reaches universal availability inside the walls in fiscal 2028, the insurance mechanism reaches the rest of the state's carceral system later, and the evaluation that justifies the $10.5 million base-budget line is due September 1, 2027 — before either is finished.

The ten million dollars for teenagers

The least discussed number in the LFC's November 2025 handout is also the hardest to defend. Between 2018 and 2023, opioid-related deaths among children aged 12 to 17 in New Mexico rose by roughly 280 percent, against 65 percent for adults. Fewer than one in three youth with a substance use disorder nationally received any treatment.

The 2025 General Appropriation Act included $10 million to be used partly for medication-assisted treatment for youth. According to the LFC, the Health Care Authority is not currently operating a juvenile MAT program; the money sits inside a regional planning appropriation. The one program the handout names — ADOBE, run through the University of New Mexico, providing wraparound services to youth who have passed through Bernalillo County's juvenile detention center — was serving 11 children.

Eleven. Against a 280 percent rise in pediatric opioid deaths.

The comparison is not quite fair, because a juvenile MAT program cannot be conjured from an appropriation, and the clinical and consent questions around buprenorphine in adolescents are real. It is still the clearest illustration of the pattern the LFC identified a year ago: New Mexico appropriates for addiction treatment faster than its agencies can spend it, and the populations with the least institutional infrastructure — youth, jails, tribal facilities — wait longest.

What the committee did not ask

Sen. Liz Stefanics, the Santa Fe Democrat, offered the only comment the coverage recorded: "I think this is extremely worthwhile if we are looking at a population that's going to integrate back into our communities."

That is the theory of the program in one sentence, and it is also the theory the data does not yet test. New Mexico can now say how many people in custody received a medication. It cannot yet say how many left custody with a prescription in hand, how many were alive six months later, or how many returned.

The state has until November 1 of each year to publish an evaluation update, and until September 1, 2027 to produce a final report. The 1,407 is the number that will be quoted in the meantime. The 815 is the number that will decide whether the program is worth its base budget — and for people leaving a New Mexico prison with an opioid use disorder, the difference between those two figures is the difference between a start and a plan.

For families trying to understand what treatment inside a correctional facility should look like on the outside, the standards are the same ones that apply in the community: medication-assisted treatment delivered with counseling, and a written plan for opioid addiction treatment that begins before release rather than after it.

RR
Rainier Rehab Editorial Team

Editorial Board

LADC, LCPC, CASAC

The Rainier Rehab editorial team consists of licensed addiction counselors, healthcare journalists, and recovery advocates dedicated to providing accurate, evidence-based information about substance abuse treatment and rehabilitation.

Related Articles